Radical metastasectomy followed by sorafenib versus observation in patients with clear cell renal cell carcinoma: extended follow up of efficacy results from the randomized phase II RESORT trial.
2021
Background: The RESORT trial showed no longer relapse free survival (RFS) with sorafenib following radical metastasectomy in metastatic renal cell carcinoma. We present the updated 42-month follow-...
Keywords:
-
Correction
-
Source
-
Cite
-
Save
26
References
1
Citations
NaN
KQI